TY - JOUR AU - Gu, Jincui AU - Xu, Siqi AU - Huang, Lixia AU - Li, Shaoli AU - Wu, Jian AU - Xu, Junwen AU - Feng, Jinlun AU - Liu, Baomo AU - Zhou, Yanbin PY - 2018 TI - Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer JF - Journal of Thoracic Disease; Vol 10, No 2 (February 14, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Background: We sought to investigate the associations between pretreatment serum Carcinoembryonic antigen (CEA) level, 18 F-Fluoro-2-deoxyglucose ( 18 F-FDG) uptake value of primary tumor and epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC). Methods: We retrospectively reviewed medical records of 210 NSCLC patients who underwent EGFR mutation test and 18 F-FDG positron emission tomography/computed tomography (PET/CT) scan before antitumor therapy. The associations between EGFR mutations and patients’ characteristics, serum CEA, PET/ CT imaging characteristics maximal standard uptake value (SUVmax) of the primary tumor were analyzed. Receiver-operating characteristic (ROC) curve was used to assess the predictive value of these factors. Results: EGFR mutations were found in 70 patients (33.3%). EGFR mutations were more common in high CEA group (CEA ≥7.0 ng/mL) than in low CEA group (CEA vs . 27.6%; P=0.05). Females (P Conclusions: Gender, histology, pretreatment serum CEA level and SUVmax are significant predictors for EGFR mutations in NSCLC. Combining these factors in predicting EGFR mutations has a moderate diagnostic accuracy, and is helpful in guiding anti-tumor treatment. UR - https://jtd.amegroups.org/article/view/18652